SPH: Shanghai Pharma Signs $165 Million Deal for ImmVira Oncolytic Virus Program

Shanghai Pharmaceuticals in-licensed China rights to an intratumoral oncolytic virus program developed by Shenzhen's ImmVira in an agreement worth up to $165 million. ImmVira's MVR-T3011 oncolytic virus program is aimed at developing novel immunotherapies for malignant solid tumors. MVR-T3011 is a genetically engineered oncolytic herpes simplex virus-1 (oHSV-1) designed to enhance the oncolytic effects of oHSV-1. Through gene recombinant technologies, the virus expresses PD-1 antibody and interleukin-12 immune modulators. More details.... Stock Symbols: (SHA: 601607; HK :02067) Share this with colleagues: